NAV

Lisaftoclax

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Lisaftoclax
DrugBank Accession Number
DB18054
Background

Lisaftoclax is a novel, orally active, selective and potent BCL-2 inhibitor

Type
Small Molecule
Groups
Investigational
Structure
Similar Structures
Weight
Average: 882.43
Monoisotopic: 881.2973604
Chemical Formula
C45H48ClN7O8S
Synonyms
  • 4-(4-((6-(4-chlorophenyl)spiro(3.5)non-6-en-7-yl)methyl)-piperazin-1-yl)-n-((3-nitro-4-(((2s)-1,4-dioxan-2-ylmethyl)amino)phenyl)sulfonyl)-2-(1hpyrrolo(2,3-b)pyridin-5-yloxy)benzamide
  • 4-{4-{[6-(4-Chlorophenyl)spiro[3.5]non-6-en-7-yl]methyl}-piperazin-1-yl}-N-{{3-nitro-4-[((2S)-1,4-dioxan-2-ylmethyl)amino]phenyl}sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
  • Benzamide, 4-(4-((6-(4-chlorophenyl)spiro(3.5)non-6-en-7-yl)methyl)-1-piperazinyl)-n-((4-(((2s)-1,4-dioxan-2-ylmethyl)amino)-3-nitrophenyl)sulfonyl)-2-(1h-pyrrolo(2,3-b)pyridin-5-yloxy)-
External IDs
  • APG 2575
  • APG-2575
  • APG2575
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
OSL3FEZ1IF
CAS number
2180923-05-9
InChI Key
FNBXDBIYRAPDPI-BHVANESWSA-N
InChI
InChI=1S/C45H48ClN7O8S/c46-33-4-2-30(3-5-33)39-25-45(12-1-13-45)14-10-32(39)28-51-16-18-52(19-17-51)34-6-8-38(42(23-34)61-35-22-31-11-15-47-43(31)49-26-35)44(54)50-62(57,58)37-7-9-40(41(24-37)53(55)56)48-27-36-29-59-20-21-60-36/h2-9,11,15,22-24,26,36,48H,1,10,12-14,16-21,25,27-29H2,(H,47,49)(H,50,54)/t36-/m0/s1
IUPAC Name
4-(4-{[6-(4-chlorophenyl)spiro[3.5]non-6-en-7-yl]methyl}piperazin-1-yl)-N-[4-({[(2S)-1,4-dioxan-2-yl]methyl}amino)-3-nitrobenzenesulfonyl]-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzamide
SMILES
[O-][N+](=O)C1=CC(=CC=C1NC[C@H]1COCCO1)S(=O)(=O)NC(=O)C1=CC=C(C=C1OC1=CN=C2NC=CC2=C1)N1CCN(CC2=C(CC3(CCC3)CC2)C2=CC=C(Cl)C=C2)CC1

References

General References
Not Available
ChemSpider
103835872

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3RecruitingTreatmentChronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)2
2RecruitingTreatmentChronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma1
2RecruitingTreatmentT-cell Prolymphocytic Leukemia (T-PLL)1
1Active Not RecruitingTreatmentChronic Lymphocytic Leukemia / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentPharmacokinetics1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP6.11Chemaxon
pKa (Strongest Acidic)4.22Chemaxon
pKa (Strongest Basic)8.1Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count11Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area181.26 Å2Chemaxon
Rotatable Bond Count12Chemaxon
Refractivity237.88 m3·mol-1Chemaxon
Polarizability92.79 Å3Chemaxon
Number of Rings9Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at September 08, 2023 20:14 / Updated at September 26, 2023 22:59